EUVIMEDEUVIMED entdecken
Open Access

CDK6-mediated endothelial cell cycle acceleration drives arteriovenous malformations in hereditary hemorrhagic telangiectasia

Sajeth Dinakaran, Sima Qutaina, Haitian Zhao, Yuefeng Tang, Zhimin Wang, Santiago Ruiz, Aya Nomura-Kitabayashi, Christine N Metz, Helen M Arthur, Stryder M Meadows, Lionel Blanc, Marie E Faughnan und 1 weitere

Nature Cardiovascular Research · 2024

DOI: 10.1038/s44161-024-00550-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nature Cardiovascular Research, 2024. Verfasst von Sajeth Dinakaran und 12 weiteren Autor:innen. Beteiligte Einrichtung: Litwin-Zucker Alzheimer's Research Center, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase 6, Telangiectasia, Hereditary Hemorrhagic, Endothelial Cells, Cell Proliferation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI), NHLBI NIH HHS, United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs (CDMRP).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Increased endothelial cell proliferation is a hallmark of arteriovenous malformations (AVMs) in hereditary hemorrhagic telangiectasia (HHT). Here, we report a cyclin-dependent kinase 6 (CDK6)-driven mechanism of cell cycle deregulation involved in endothelial cell proliferation and HHT pathology. Specifically, endothelial cells from the livers of HHT mice bypassed the G1/S checkpoint and progressed through the cell cycle at an accelerated pace. Phosphorylated retinoblastoma (pRB1)-a marker of G1/S transition through the restriction point-accumulated in endothelial cells from retinal AVMs of HHT mice and endothelial cells from skin telangiectasia samples from HHT patients. Mechanistically, inhibition of activin receptor-like kinase 1 signaling increased key restriction point mediators, and treatment with the CDK4/6 inhibitors palbociclib or ribociclib blocked increases in pRB1 and retinal AVMs in HHT mice. Palbociclib also improved vascular pathology in the brain and liver, and slowed cell cycle progression in endothelial cells and endothelial cell proliferation. Endothelial cell-specific deletion of CDK6 was sufficient to protect HHT mice from AVM pathology. Thus, clinically approved CDK4/6 inhibitors might have the potential to be repurposed for HHT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclin-Dependent Kinase 6Telangiectasia, Hereditary HemorrhagicEndothelial CellsCell ProliferationArteriovenous MalformationsDisease Models, AnimalAnimalsHumansProtein Kinase InhibitorsPyridinesSignal TransductionPiperazinesPhosphorylationMice, KnockoutRetinoblastoma ProteinMiceRetinal VesselsCell CycleMice, Inbred C57BLCells, CulturedActivin Receptors, Type IIMale

Substanzen

Cyclin-Dependent Kinase 6CDK6 protein, humanProtein Kinase InhibitorsPyridinespalbociclibCdk6 protein, mousePiperazinesRetinoblastoma ProteinAcvrl1 protein, mouseACVRL1 protein, human

Autor:innen und Institutionen

  • Litwin-Zucker Alzheimer's Research Center, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA.
  • Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
  • Institute of Molecular Medicine, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA.
  • Laboratory of Metabolic Diseases and Aging, Institut Pasteur de Montevideo, Montevideo, Uruguay.
  • Biosciences Institute, Newcastle University, Newcastle, UK.
  • Cell and Molecular Biology Department, Tulane University, New Orleans, LA, USA.

Förderung

  • U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)
  • NHLBI NIH HHS
  • United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs (CDMRP)

Zitieren

APA

Dinakaran, S., Qutaina, S., Zhao, H., Tang, Y., Wang, Z., Ruiz, S., Nomura-Kitabayashi, A., Metz, C. N., Arthur, H. M., Meadows, S. M., Blanc, L., Faughnan, M. E., & Marambaud, P. (2024). CDK6-mediated endothelial cell cycle acceleration drives arteriovenous malformations in hereditary hemorrhagic telangiectasia. Nature Cardiovascular Research. https://doi.org/10.1038/s44161-024-00550-9

Vancouver

Dinakaran S, Qutaina S, Zhao H, Tang Y, Wang Z, Ruiz S, et al. CDK6-mediated endothelial cell cycle acceleration drives arteriovenous malformations in hereditary hemorrhagic telangiectasia. Nature Cardiovascular Research. 2024. doi:10.1038/s44161-024-00550-9

BibTeX
@article{Dinakaran2024,
  author = {Dinakaran, Sajeth and Qutaina, Sima and Zhao, Haitian and Tang, Yuefeng and Wang, Zhimin and Ruiz, Santiago and Nomura-Kitabayashi, Aya and Metz, Christine N and Arthur, Helen M and Meadows, Stryder M and Blanc, Lionel and Faughnan, Marie E and Marambaud, Philippe},
  title = {CDK6-mediated endothelial cell cycle acceleration drives arteriovenous malformations in hereditary hemorrhagic telangiectasia},
  journal = {Nature Cardiovascular Research},
  year = {2024},
  doi = {10.1038/s44161-024-00550-9}
}
Kostenlos starten →